{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T06:38:45Z","timestamp":1793342325831,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Peter E. Schwartz Discovery to Cure Program, Yale University, United States"},{"name":"Rivkin Center for Ovarian Cancer Research, United States"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-06812-1","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T11:06:12Z","timestamp":1751367972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["CXCL10-induced regulatory T cells and adenosine signaling promote immunosuppression and progression of epithelial ovarian cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Annabelle C.","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jake","family":"Moscarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Lian","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Ping","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena S.","family":"Ratner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"6812_CR1","doi-asserted-by":"publisher","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E., Jemal, A. & Cancer statistics CA: A Cancer Journal for Clinicians 72, 7\u201333, (2022). https:\/\/doi.org\/10.3322\/caac.21708 (2022).","DOI":"10.3322\/caac.21708"},{"key":"6812_CR2","doi-asserted-by":"publisher","first-page":"5527","DOI":"10.1158\/0008-5472.CAN-05-4128","volume":"66","author":"R Kim","year":"2006","unstructured":"Kim, R., Emi, M., Tanabe, K. & Arihiro, K. Tumor-Driven evolution of immunosuppressive networks during malignant progression. Cancer Res. 66, 5527\u20135536 (2006).","journal-title":"Cancer Res."},{"key":"6812_CR3","doi-asserted-by":"crossref","unstructured":"Zhang, Y. & Zheng, J. in Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy (ed Jie Xu) 201\u2013226Springer Singapore, (2020).","DOI":"10.1007\/978-981-15-3266-5_9"},{"key":"6812_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1146\/annurev-cancerbio-030617-050606","volume":"2","author":"S Spranger","year":"2018","unstructured":"Spranger, S. & Gajewski, T. F. Mechanisms of tumor Cell\u2013Intrinsic immune evasion. Annual Rev. Cancer Biology. 2, 213\u2013228. https:\/\/doi.org\/10.1146\/annurev-cancerbio-030617-050606 (2018).","journal-title":"Annual Rev. Cancer Biology"},{"key":"6812_CR5","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1158\/2159-8290.cd-18-0367","volume":"8","author":"SC Wei","year":"2018","unstructured":"Wei, S. C., Duffy, C. R. & Allison, J. P. Fundamental mechanisms of immune checkpoint Blockade therapy. Cancer Discov. 8, 1069\u20131086. https:\/\/doi.org\/10.1158\/2159-8290.cd-18-0367 (2018).","journal-title":"Cancer Discov."},{"key":"6812_CR6","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4049\/jimmunol.154.1.97","volume":"154","author":"LL Lanier","year":"1995","unstructured":"Lanier, L. L. et al. CD80 (B7) and CD86 (B70) provide similar costimulatory signals for T cell proliferation, cytokine production, and generation of CTL. J. Immunol. (Baltimore Md. : 1950). 154, 97\u2013105 (1995).","journal-title":"J. Immunol. (Baltimore Md. : 1950)"},{"key":"6812_CR7","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman, G. J. et al. Engagement of the PD-1 Immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med. 192, 1027\u20131034 (2000).","journal-title":"J. Exp. Med."},{"key":"6812_CR8","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/mcb.25.21.9543-9553.2005","volume":"25","author":"RV Parry","year":"2005","unstructured":"Parry, R. V. et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol. 25, 9543\u20139553. https:\/\/doi.org\/10.1128\/mcb.25.21.9543-9553.2005 (2005).","journal-title":"Mol. Cell. Biol."},{"key":"6812_CR9","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1126\/science.aaf1292","volume":"355","author":"E Hui","year":"2017","unstructured":"Hui, E. et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated Inhibition. Sci. (New York N Y). 355, 1428\u20131433. https:\/\/doi.org\/10.1126\/science.aaf1292 (2017).","journal-title":"Sci. (New York N Y)"},{"key":"6812_CR10","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nri2343","volume":"8","author":"DA Vignali","year":"2008","unstructured":"Vignali, D. A., Collison, L. W. & Workman, C. J. How regulatory T cells work. Nat. Rev. Immunol. 8, 523\u2013532. https:\/\/doi.org\/10.1038\/nri2343 (2008).","journal-title":"Nat. Rev. Immunol."},{"key":"6812_CR11","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1038\/ni1536","volume":"8","author":"P Pandiyan","year":"2007","unstructured":"Pandiyan, P., Zheng, L., Ishihara, S., Reed, J. & Lenardo, M. J. CD4\u2009+\u2009CD25\u2009+\u2009Foxp3\u2009+\u2009regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4\u2009+\u2009T cells. Nat. Immunol. 8, 1353\u20131362. https:\/\/doi.org\/10.1038\/ni1536 (2007).","journal-title":"Nat. Immunol."},{"key":"6812_CR12","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.4049\/jimmunol.169.5.2253","volume":"169","author":"R Lang","year":"2002","unstructured":"Lang, R., Patel, D., Morris, J. J., Rutschman, R. L. & Murray, P. J. Shaping gene expression in activated and resting primary macrophages by IL-10. J. Immunol. 169, 2253\u20132263. https:\/\/doi.org\/10.4049\/jimmunol.169.5.2253 (2002).","journal-title":"J. Immunol."},{"key":"6812_CR13","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1038\/nm1001-1118","volume":"7","author":"L Gorelik","year":"2001","unstructured":"Gorelik, L. & Flavell, R. A. Immune-mediated eradication of tumors through the Blockade of transforming growth factor-\u03b2 signaling in T cells. Nat. Med. 7, 1118\u20131122. https:\/\/doi.org\/10.1038\/nm1001-1118 (2001).","journal-title":"Nat. Med."},{"key":"6812_CR14","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1038\/s41416-019-0444-3","volume":"120","author":"L Heim","year":"2019","unstructured":"Heim, L. et al. Increased expression of the immunosuppressive interleukin-35 in patients with non-small cell lung cancer. Br. J. Cancer. 120, 903\u2013912. https:\/\/doi.org\/10.1038\/s41416-019-0444-3 (2019).","journal-title":"Br. J. Cancer"},{"key":"6812_CR15","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1016\/j.immuni.2007.08.014","volume":"27","author":"X Cao","year":"2007","unstructured":"Cao, X. et al. Granzyme B and Perforin are important for regulatory T Cell-Mediated suppression of tumor clearance. Immunity 27, 635\u2013646. https:\/\/doi.org\/10.1016\/j.immuni.2007.08.014 (2007).","journal-title":"Immunity"},{"key":"6812_CR16","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1084\/jem.20082492","volume":"206","author":"KS Peggs","year":"2009","unstructured":"Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J. & Allison, J. P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med. 206, 1717\u20131725. https:\/\/doi.org\/10.1084\/jem.20082492 (2009).","journal-title":"J. Exp. Med."},{"key":"6812_CR17","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.jaut.2013.06.006","volume":"45","author":"LS Walker","year":"2013","unstructured":"Walker, L. S. & Treg CTLA-4: two intertwining pathways to immune tolerance. J. Autoimmun. 45, 49\u201357. https:\/\/doi.org\/10.1016\/j.jaut.2013.06.006 (2013).","journal-title":"J. Autoimmun."},{"key":"6812_CR18","doi-asserted-by":"publisher","first-page":"e173290","DOI":"10.1001\/jamaoncol.2017.3290","volume":"3","author":"OTTA Consortium","year":"2017","unstructured":"Consortium, O. T. T. A. Dose-Response association of CD8\u2009+\u2009Tumor-Infiltrating lymphocytes and survival time in High-Grade serous ovarian Cancer. JAMA Oncol. 3, e173290\u2013e173290. https:\/\/doi.org\/10.1001\/jamaoncol.2017.3290 (2017).","journal-title":"JAMA Oncol."},{"key":"6812_CR19","doi-asserted-by":"publisher","first-page":"4351","DOI":"10.1158\/0008-5472.can-12-0579","volume":"72","author":"N Redjimi","year":"2012","unstructured":"Redjimi, N. et al. CXCR3\u2009+\u2009T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity. Cancer Res. 72, 4351\u20134360. https:\/\/doi.org\/10.1158\/0008-5472.can-12-0579 (2012).","journal-title":"Cancer Res."},{"key":"6812_CR20","doi-asserted-by":"publisher","first-page":"282","DOI":"10.3389\/fcell.2020.00282","volume":"8","author":"Q Wu","year":"2020","unstructured":"Wu, Q., Li, B., Sun, S. & Sun, S. Unraveling adipocytes and Cancer links: is there a role for senescence?? Front. Cell. Dev. Biology. 8, 282. https:\/\/doi.org\/10.3389\/fcell.2020.00282 (2020).","journal-title":"Front. Cell. Dev. Biology"},{"key":"6812_CR21","doi-asserted-by":"publisher","first-page":"830208","DOI":"10.3389\/fcell.2022.830208","volume":"10","author":"K Park","year":"2022","unstructured":"Park, K., Veena, M. S. & Shin, D. S. Key players of the immunosuppressive tumor microenvironment and emerging therapeutic strategies. Front. Cell. Dev. Biology. 10, 830208. https:\/\/doi.org\/10.3389\/fcell.2022.830208 (2022).","journal-title":"Front. Cell. Dev. Biology"},{"key":"6812_CR22","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","volume":"32","author":"JW Griffith","year":"2014","unstructured":"Griffith, J. W., Sokol, C. L. & Luster, A. D. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 32, 659\u2013702. https:\/\/doi.org\/10.1146\/annurev-immunol-032713-120145 (2014).","journal-title":"Annu. Rev. Immunol."},{"key":"6812_CR23","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.yexcr.2010.12.017","volume":"317","author":"JR Groom","year":"2011","unstructured":"Groom, J. R. & Luster, A. D. CXCR3 in T cell function. Exp. Cell Res. 317, 620\u2013631. https:\/\/doi.org\/10.1016\/j.yexcr.2010.12.017 (2011).","journal-title":"Exp. Cell Res."},{"key":"6812_CR24","doi-asserted-by":"publisher","first-page":"5602","DOI":"10.4049\/jimmunol.1201018","volume":"189","author":"E Schlecker","year":"2012","unstructured":"Schlecker, E. et al. Tumor-infiltrating monocytic myeloid-derived suppressor cells mediate CCR5-dependent recruitment of regulatory T cells favoring tumor growth. J. Immunol. (Baltimore Md. : 1950). 189, 5602\u20135611. https:\/\/doi.org\/10.4049\/jimmunol.1201018 (2012).","journal-title":"J. Immunol. (Baltimore Md. : 1950)"},{"key":"6812_CR25","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1084\/jem.166.4.1084","volume":"166","author":"AD Luster","year":"1987","unstructured":"Luster, A. D. & Ravetch, J. V. Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J. Exp. Med. 166, 1084\u20131097. https:\/\/doi.org\/10.1084\/jem.166.4.1084 (1987).","journal-title":"J. Exp. Med."},{"key":"6812_CR26","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3892\/ol.2011.300","volume":"2","author":"M Liu","year":"2011","unstructured":"Liu, M., Guo, S. & Stiles, J. K. The emerging role of CXCL10 in cancer (Review). Oncol. Lett. 2, 583\u2013589. https:\/\/doi.org\/10.3892\/ol.2011.300 (2011).","journal-title":"Oncol. Lett."},{"key":"6812_CR27","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1517\/14728222.2013.837886","volume":"17","author":"RE Marques","year":"2013","unstructured":"Marques, R. E., Guabiraba, R., Russo, R. C. & Teixeira, M. M. Targeting CCL5 in inflammation. Expert Opin. Ther. Targets. 17, 1439\u20131460. https:\/\/doi.org\/10.1517\/14728222.2013.837886 (2013).","journal-title":"Expert Opin. Ther. Targets"},{"key":"6812_CR28","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1016\/j.immuni.2023.06.003","volume":"56","author":"MA Moreno Ayala","year":"2023","unstructured":"Moreno Ayala, M. A. et al. CXCR3 expression in regulatory T cells drives interactions with type I dendritic cells in tumors to restrict CD8(+) T cell antitumor immunity. Immunity 56, 1613\u20131630e1615. https:\/\/doi.org\/10.1016\/j.immuni.2023.06.003 (2023).","journal-title":"Immunity"},{"key":"6812_CR29","doi-asserted-by":"publisher","first-page":"e1027473","DOI":"10.1080\/2162402x.2015.1027473","volume":"4","author":"S Lunardi","year":"2015","unstructured":"Lunardi, S., Lim, S. Y., Muschel, R. J. & Brunner, T. B. IP-10\/CXCL10 attracts regulatory T cells: implication for pancreatic cancer. Oncoimmunology 4, e1027473. https:\/\/doi.org\/10.1080\/2162402x.2015.1027473 (2015).","journal-title":"Oncoimmunology"},{"key":"6812_CR30","doi-asserted-by":"publisher","first-page":"18007","DOI":"10.1038\/s41598-021-97390-5","volume":"11","author":"M Kim","year":"2021","unstructured":"Kim, M., Choi, H. Y., Woo, J. W., Chung, Y. R. & Park, S. Y. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast. Sci. Rep. 11, 18007. https:\/\/doi.org\/10.1038\/s41598-021-97390-5 (2021).","journal-title":"Sci. Rep."},{"key":"6812_CR31","doi-asserted-by":"publisher","unstructured":"Tan, M. C. et al. Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. Journal of immunology (Baltimore, Md.:) 182, 1746\u20131755, ) 182, 1746\u20131755, (1950). https:\/\/doi.org\/10.4049\/jimmunol.182.3.1746 (2009).","DOI":"10.4049\/jimmunol.182.3.1746"},{"key":"6812_CR32","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.celrep.2017.04.031","volume":"19","author":"A Garcia-Diaz","year":"2017","unstructured":"Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell. Rep. 19, 1189\u20131201. https:\/\/doi.org\/10.1016\/j.celrep.2017.04.031 (2017).","journal-title":"Cell. Rep."},{"key":"6812_CR33","doi-asserted-by":"publisher","unstructured":"Kciuk, M. et al. PD-1\/PD-L1 and DNA damage response in Cancer. Cells 12 https:\/\/doi.org\/10.3390\/cells12040530 (2023).","DOI":"10.3390\/cells12040530"},{"key":"6812_CR34","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1016\/j.chembiol.2006.09.018","volume":"13","author":"J Schust","year":"2006","unstructured":"Schust, J., Sperl, B., Hollis, A., Mayer, T. U. & Berg, T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 13, 1235\u20131242. https:\/\/doi.org\/10.1016\/j.chembiol.2006.09.018 (2006).","journal-title":"Chem. Biol."},{"key":"6812_CR35","doi-asserted-by":"publisher","first-page":"4969","DOI":"10.1073\/pnas.84.14.4969","volume":"84","author":"D Kozbor","year":"1987","unstructured":"Kozbor, D., Burioni, R., Ar-Rushdi, A., Zmijewski, C. & Croce, C. M. Expression of members of Immunoglobulin gene family in somatic cell hybrids between human B and T cells. Proc. Natl. Acad. Sci. U S A. 84, 4969\u20134973. https:\/\/doi.org\/10.1073\/pnas.84.14.4969 (1987).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"6812_CR36","doi-asserted-by":"crossref","unstructured":"Islam, S. et al. Co-targeting aurora kinase with PD-L1 and PI3K abrogates immune checkpoint mediated proliferation in peripheral T-cell lymphoma: a novel therapeutic strategy. Oncotarget 8 (2017).","DOI":"10.18632\/oncotarget.22222"},{"key":"6812_CR37","doi-asserted-by":"publisher","first-page":"5698","DOI":"10.1073\/pnas.96.10.5698","volume":"96","author":"M Baba","year":"1999","unstructured":"Baba, M. et al. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc. Natl. Acad. Sci. U S A. 96, 5698\u20135703. https:\/\/doi.org\/10.1073\/pnas.96.10.5698 (1999).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"6812_CR38","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1016\/j.bmcl.2007.03.106","volume":"17","author":"M Johnson","year":"2007","unstructured":"Johnson, M. et al. Discovery and optimization of a series of quinazolinone-derived antagonists of CXCR3. Bioorg. Med. Chem. Lett. 17, 3339\u20133343. https:\/\/doi.org\/10.1016\/j.bmcl.2007.03.106 (2007).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"6812_CR39","doi-asserted-by":"publisher","unstructured":"Ng, T. H. S. et al. Regulation of adaptive immunity; the role of Interleukin-10. Front. Immunol. 4 https:\/\/doi.org\/10.3389\/fimmu.2013.00129 (2013).","DOI":"10.3389\/fimmu.2013.00129"},{"key":"6812_CR40","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/S0022-3565(25)39174-3","volume":"242","author":"G Ghai","year":"1987","unstructured":"Ghai, G. et al. Pharmacological characterization of CGS 15943A: a novel nonxanthine adenosine antagonist. J. Pharmacol. Exp. Ther. 242, 784\u2013790 (1987).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"6812_CR41","unstructured":"The Human Protein Atlas. https:\/\/www.proteinatlas.org\/ENSG00000128271-ADORA2A\/single+cell\/t-cells"},{"key":"6812_CR42","unstructured":"The Human Protein Atlas. https:\/\/www.proteinatlas.org\/ENSG00000128271-ADORA2A\/cell+line#leukemia"},{"key":"6812_CR43","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard, B., Longhi, M. S., Robson, S. C. & Stagg, J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol. Rev. 276, 121\u2013144. https:\/\/doi.org\/10.1111\/imr.12528 (2017).","journal-title":"Immunol. Rev."},{"key":"6812_CR44","unstructured":"The Human Protein Atlas. https:\/\/www.proteinatlas.org\/ENSG00000186810-CXCR3\/single+cell#immune_cell"},{"key":"6812_CR45","unstructured":"The Human Protein Atlas. https:\/\/www.proteinatlas.org\/ENSG00000160791-CCR5\/single+cell#immune_cell"},{"key":"6812_CR46","unstructured":"The Single Cell Portal. https:\/\/singlecell.broadinstitute.org\/single_cell\/study\/SCP424\/single-cell-comparison-pbmc-data?genes=FOXP3%2CCD4%2CCD8A%2CIL2RA%2CCD3E%2CCXCR3%2CCCR5&tab=dotplot#study-visualize."},{"key":"6812_CR47","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/0008-5472.can-16-1272","volume":"76","author":"J Walton","year":"2016","unstructured":"Walton, J. et al. CRISPR\/Cas9-Mediated Trp53 and Brca2 knockout to generate improved murine models of ovarian High-Grade serous carcinoma. Cancer Res. 76, 6118\u20136129. https:\/\/doi.org\/10.1158\/0008-5472.can-16-1272 (2016).","journal-title":"Cancer Res."},{"key":"6812_CR48","doi-asserted-by":"publisher","first-page":"16827","DOI":"10.1038\/s41598-017-17119-1","volume":"7","author":"JB Walton","year":"2017","unstructured":"Walton, J. B. et al. CRISPR\/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity. Sci. Rep. 7, 16827. https:\/\/doi.org\/10.1038\/s41598-017-17119-1 (2017).","journal-title":"Sci. Rep."},{"key":"6812_CR49","doi-asserted-by":"publisher","first-page":"e0207399","DOI":"10.1371\/journal.pone.0207399","volume":"13","author":"ZP Lin","year":"2018","unstructured":"Lin, Z. P. et al. Combination of triapine, olaparib, and cediranib suppresses progression of BRCA-wild type and PARP inhibitor-resistant epithelial ovarian cancer. PloS One. 13, e0207399. https:\/\/doi.org\/10.1371\/journal.pone.0207399 (2018).","journal-title":"PloS One"},{"key":"6812_CR50","doi-asserted-by":"publisher","first-page":"616837","DOI":"10.3389\/fimmu.2021.616837","volume":"12","author":"M Bourhis","year":"2021","unstructured":"Bourhis, M., Palle, J., Galy-Fauroux, I. & Terme, M. Direct and indirect modulation of T cells by VEGF-A counteracted by Anti-Angiogenic treatment. Front. Immunol. 12, 616837. https:\/\/doi.org\/10.3389\/fimmu.2021.616837 (2021).","journal-title":"Front. Immunol."},{"key":"6812_CR51","first-page":"6166","volume":"48","author":"SP Langdon","year":"1988","unstructured":"Langdon, S. P. et al. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res. 48, 6166\u20136172 (1988).","journal-title":"Cancer Res."},{"key":"6812_CR52","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1038\/nature06633","volume":"451","author":"W Sakai","year":"2008","unstructured":"Sakai, W. et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 451, 1116\u20131120 (2008). Epub 2008 Feb 1110.","journal-title":"Nature"},{"key":"6812_CR53","doi-asserted-by":"publisher","first-page":"8042","DOI":"10.1038\/s41598-021-87325-5","volume":"11","author":"ZP Lin","year":"2021","unstructured":"Lin, Z. P. et al. In Silico screening identifies a novel small molecule inhibitor that counteracts PARP inhibitor resistance in ovarian cancer. Sci. Rep. 11, 8042. https:\/\/doi.org\/10.1038\/s41598-021-87325-5 (2021).","journal-title":"Sci. Rep."},{"key":"6812_CR54","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1189\/jlb.2MR0915-441R","volume":"99","author":"N Karin","year":"2016","unstructured":"Karin, N., Wildbaum, G. & Thelen, M. Biased signaling pathways via CXCR3 control the development and function of CD4\u2009+\u2009T cell subsets. J. Leukoc. Biol. 99, 857\u2013862. https:\/\/doi.org\/10.1189\/jlb.2MR0915-441R (2016).","journal-title":"J. Leukoc. Biol."},{"key":"6812_CR55","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1182\/blood-2009-01-197178","volume":"114","author":"X Chen","year":"2009","unstructured":"Chen, X. et al. Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host disease. Blood 114, 891\u2013900. https:\/\/doi.org\/10.1182\/blood-2009-01-197178 (2009).","journal-title":"Blood"},{"key":"6812_CR56","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1002\/eji.201040391","volume":"40","author":"A Kimura","year":"2010","unstructured":"Kimura, A. & Kishimoto, T. IL-6: regulator of Treg\/Th17 balance. Eur. J. Immunol. 40, 1830\u20131835. https:\/\/doi.org\/10.1002\/eji.201040391 (2010).","journal-title":"Eur. J. Immunol."},{"key":"6812_CR57","doi-asserted-by":"publisher","first-page":"18460","DOI":"10.1073\/pnas.0809850105","volume":"105","author":"T Korn","year":"2008","unstructured":"Korn, T. et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3\u2009+\u2009regulatory T cells. Proc. Natl. Acad. Sci. U S A. 105, 18460\u201318465. https:\/\/doi.org\/10.1073\/pnas.0809850105 (2008).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"6812_CR58","doi-asserted-by":"publisher","first-page":"6381","DOI":"10.1158\/0008-5472.can-09-1178","volume":"69","author":"W Sakai","year":"2009","unstructured":"Sakai, W. et al. Functional restoration of BRCA2 protein by secondary BRCA2 mutations in BRCA2-mutated ovarian carcinoma. Cancer Res. 69, 6381\u20136386. https:\/\/doi.org\/10.1158\/0008-5472.can-09-1178 (2009).","journal-title":"Cancer Res."},{"key":"6812_CR59","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jhep.2016.05.032","volume":"65","author":"CX Li","year":"2016","unstructured":"Li, C. X. et al. CXCL10\/CXCR3 signaling mobilized-regulatory T cells promote liver tumor recurrence after transplantation. J. Hepatol. 65, 944\u2013952. https:\/\/doi.org\/10.1016\/j.jhep.2016.05.032 (2016).","journal-title":"J. Hepatol."},{"key":"6812_CR60","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1183\/09031936.00111507","volume":"31","author":"Y Suzaki","year":"2008","unstructured":"Suzaki, Y. et al. A small-molecule compound targeting CCR5 and CXCR3 prevents airway hyperresponsiveness and inflammation. Eur. Respir. J. 31, 783\u2013789. https:\/\/doi.org\/10.1183\/09031936.00111507 (2008).","journal-title":"Eur. Respir. J."},{"key":"6812_CR61","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1182\/blood.V90.4.1600","volume":"90","author":"S Huang","year":"1997","unstructured":"Huang, S., Apasov, S., Koshiba, M. & Sitkovsky, M. Role of A2a extracellular adenosine receptor-mediated signaling in adenosine-mediated Inhibition of T-cell activation and expansion. Blood 90, 1600\u20131610 (1997).","journal-title":"Blood"},{"key":"6812_CR62","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3892\/ol.2022.13489","volume":"24","author":"D Ribatti","year":"2022","unstructured":"Ribatti, D. Immunosuppressive effects of vascular endothelial growth factor. Oncol. Lett. 24, 369. https:\/\/doi.org\/10.3892\/ol.2022.13489 (2022).","journal-title":"Oncol. Lett."},{"key":"6812_CR63","doi-asserted-by":"publisher","unstructured":"Hosen, S. M. Z. et al. Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: key role of the urokinase plasminogen activator (PLAU). Front. Immunol. 13 https:\/\/doi.org\/10.3389\/fimmu.2022.1060957 (2022).","DOI":"10.3389\/fimmu.2022.1060957"},{"key":"6812_CR64","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.immuni.2017.11.016","volume":"47","author":"MA Coelho","year":"2017","unstructured":"Coelho, M. A. et al. Oncogenic RAS signaling promotes tumor immunoresistance by stabilizing PD-L1 mRNA. Immunity 47, 1083\u20131099e1086. https:\/\/doi.org\/10.1016\/j.immuni.2017.11.016 (2017).","journal-title":"Immunity"}],"updated-by":[{"DOI":"10.1038\/s41598-025-12693-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T00:00:00Z","timestamp":1753228800000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06812-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06812-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T00:10:27Z","timestamp":1757203827000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-06812-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":64,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6812"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-06812-1","relation":{"correction":[{"id-type":"doi","id":"10.1038\/s41598-025-12693-1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"21 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-025-12693-1","URL":"https:\/\/doi.org\/10.1038\/s41598-025-12693-1","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20778"}}